IIVS, Non Animal Testing, Alternative Test Methods, In Vitro Toxicology | Assays Mucin Production
102
archive,tax-assay,term-mucin-production,term-102,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

Archive

Holger Behrsing, PhD, Participates in Round Table Discussion on Non-Animal Approaches for Inhalation Toxicology

June 14, 2018
Holger Behrsing, PhD, was recently invited to participate in an expert round table discussion convened on the development and implementation of 21st century non-animal approaches to assess the toxicity of inhaled substances.  The discussion included perspectives from government, industry, nonprofit, and academic sectors on the advantages and challenges of using these approaches, ongoing efforts, and steps needed to gain widespread use and acceptance of these approaches. A transcript of the discussion has just been published in Applied In Vitro Toxicology, Vol....

Webinar: How GLPs Enhance the Quality of Regulated and Non-Regulated Toxicology

October 18, 2016
This one-hour webinar, led by IIVS Director of Quality and Compliance, introduces some of the concepts of Good Laboratory Practices (GLPs) designed to promote study and data integrity within an in vitro toxicology framework. Applying these concepts within your own laboratory should aid in production of robust, repeatable studies. View Slides...

Acute Respiratory Toxicity

August 24, 2016
Exposure of lung tissue to materials, inhaled or otherwise, may challenge the tissue leading to cell death or loss of viability. IIVS’s Respiratory Toxicology Program offers several pulmonary models that will allow the assessment of cytotoxicity or viability loss after tissue exposure to test articles. These acute toxicity endpoints are available for all pulmonary models utilized within Respiratory Toxicology. Cytotoxicity manifests as a loss of membrane integrity and results in the release of intracellular constituents. Respiratory tissue exposed to a test material...

Next Generation Tobacco Products

August 24, 2016
IIVS has a long-standing history of working with various industries to help establish or utilize in vitro models for the prediction of risk and the assessment of products under development. With the Food and Drug Administration extending its authority to all tobacco products (including e-cigarettes, cigars, and hookah) the tobacco industry is faced with the task of assessing product safety for product development and regulatory submission. Further, the manufacture of tobacco products may entail risk to workers that come in...